Order results by:
Issue | Title | |
Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
M. Yu. Frolov, V. A. Rogov | ||
"... Excel model. CER compared lenvatinib 24 mg/daily, sorafenib 800 mg/daily and Other chemotherapies mix ..." | ||
Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
M. Yu. Frolov, V. A. Rogov | ||
"... analysis (BIA), two scenarios were simulated: 1. DTC treatment using sorafenib and the chemotherapeutic ..." | ||
Vol 10, No 4 (2017) | SOURCES OF BIAS IN SELF-ASSESSED HEALTH | Abstract similar documents |
C. J. Gerry, V. M. Baydin | ||
"... and quality of life of the population. However, SAH is a subjective indicator and subject to bias stemming ..." | ||
Vol 9, No 4 (2016) | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION | Abstract similar documents |
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya | ||
Vol 8, No 1 (2015) | BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract similar documents |
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina | ||
"... We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine ..." | ||
Online First | Artificial intelligence in healthcare: global implementation, legal regulation, problems and ethical issues | Abstract similar documents |
D. I. Korabelnikov, A. I. Lamotkin | ||
"... and an emerging framework in Russia. Key issues were emphasized, such as algorithmic bias, AI transparency ..." | ||
Vol 16, No 2 (2023) | Pharmacoeconomic study of various treatment options for superficial vein thrombophlebitis of lower extremities | Abstract similar documents |
R. E. Kalinin, I. A. Suchkov, M. M. Uporov, D. S. Titov, M. Yu. Klishchenko | ||
"... the costeffectiveness ratio (CER). The relapse/progression of the disease within 3 months after the end of treatment ..." | ||
Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract similar documents |
A. Yu. Kulikov, I. Yu. Zinchuk | ||
"... , Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment ..." | ||
Vol 10, No 1 (2017) | CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS | Abstract similar documents |
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova | ||
"... that of eribulin, and even at mid-optimal doses (1.5 mg/m2 ) exceeded 2xWPT. The cost estimating relationship (CER ..." | ||
Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
R. I. Yagudina, M. M. Murashko | ||
"... as the effectiveness criterion. The CER amounted to 440,759 roubles for Reamberin, 543,991 roubles for the Ringer ..." | ||
Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
O. V. Zhukova, S. V. Kononova | ||
"... ’s course of therapy characterized by a lower value CER in comparison with Amoxiklav. From ..." | ||
Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
"... (BIA), several options for managing patients with infertility were considered: current practice (in 100 ..." | ||
Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
"... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
"... of the knee with Chondroguard® is the most economically feasible in terms of the cost-effectiveness ratio (CER ..." | ||
Vol 16, No 4 (2023) | Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C | Abstract similar documents |
I. A. Narkevich, E. A. Tsitlionok | ||
"... of therapy was assessed by calculating the cost-effectiveness ratio (CER). Results. A retrospective analysis ..." | ||
Vol 16, No 4 (2023) | Pharmacoeconomic study of fluorescent lymphography and radionuclide diagnostics methods for sentinel lymph node detection in breast cancer | Abstract similar documents |
E. P. Kulikov, M. V. Shomova, D. S. Titov, A. N. Demko, M. A. Maistrenko | ||
"... ). Material and methods. The values of the cost-effectiveness ratio (CER) were calculated and compared ..." | ||
Vol 14, No 2 (2021) | Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region | Abstract similar documents |
A. D. Ermolaeva, V. S. Krysanova, T. N. Ermolaeva, K. I. Polyakova, K. A. Kokushkin | ||
"... hospital (DH). Budget impact analysis (BIA) was performed to provide scientific and economic feasibility ..." | ||
Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
"... disappears, and the CA drugs have a lower CER instead. For the «number of hospitalization-free days per year ..." | ||
Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
"... was increased to 24 months, this economic advantage of AA diminished, and the kA drugs had a lower CeR instead ..." | ||
Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
"... values of savings in direct medical costs and the cost-effectiveness ratio (CER) were evaluated ..." | ||
Vol 17, No 3 (2024) | Artificial intelligence: basic terms and concepts, the application in healthcare and clinical medicine | Abstract similar documents |
A. I. Lamotkin, D. I. Korabelnikov, I. A. Lamotkin | ||
"... availability and bias, fragmentation of systems, and complexity of algorithm interpretation. Conclusion ..." | ||
1 - 21 of 21 Items |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)